Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2021 Feb;18(2):67-68.
doi: 10.1038/s41571-020-00453-1.

CDK4/6 inhibitors for HR+HER2- early stage breast cancer - when to escalate treatment?

Giuseppe Curigliano  1   2
Affiliations
Comment

CDK4/6 inhibitors for HR+HER2- early stage breast cancer - when to escalate treatment?

Giuseppe Curigliano. Nat Rev Clin Oncol. 2021 Feb.
No abstract available

PubMed Disclaimer

Comment on

References

    1. Finn, R. S. et al. Palbociclib and letrozole in advanced breast cancer. N. Engl. J. Med. 375, 1925–1936 (2016). - DOI
    1. Turner, N. C. et al. Overall survival with palbociclib and fulvestrant in advanced breast cancer. N. Engl. J. Med. 379, 1926–1936 (2018). - DOI
    1. Sledge, G. W. Jr et al. MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy. J. Clin. Oncol. 35, 2875–2884 (2017). - DOI
    1. Sledge, G. W. Jr et al. The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy — MONARCH 2: a randomized clinical trial. JAMA Oncol. 6, 116–124 (2020). - DOI
    1. Goetz, M. P. et al. MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J. Clin. Oncol. 35, 3638–3646 (2017). - DOI